Business highlights in Q1 2026

• In February the Company announced that the European Patent Office (EPO) has granted the Company’s European patent application covering pudafensine for the treatment of Female Sexual Dysfunction (FSD)

Business highlights after this reporting period

• In April the Company announced that the company has decided to focus fully on its most promising drug candidate, pudafensine, which is being developed for both vulvodynia and organic erectile dysfunction (ED). As part of this prioritization, the Company will discontinue further development of IP2018
• In April the Company announced good progress in patient enrolment in its Phase IIa clinical proof-of-concept study evaluating pudafensine in women suffering from the genital pain condition, vulvodynia

Financial Highlights

Solidity: equity divided by assets.

The Board of Directors have decided that interim reports will be published in English only.

Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of one clinical stage assets – pudafensine – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye Sweden AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

INIT 2026 Q1 Final